Lipella Pharmaceuticals Inc. LIPO

Overview

Lipella Pharmaceuticals Inc. is a biotechnology company that specializes in the development of innovative drug formulations. The company implements a strategy of reformulating the active ingredients in generic drugs to create optimized versions for various medical applications. Established in 2005, Lipella Pharmaceuticals has its headquarters in Pittsburgh, Pennsylvania. The company's research and development focus is primarily geared towards providing solutions for conditions that are currently underserved by the pharmaceutical market. Through its commitment to innovation and patient care, Lipella Pharmaceuticals strives to address the needs of patients suffering from specific medical conditions by leveraging existing pharmacological knowledge and applying it in novel ways.

Products and Services

Lipella Pharmaceuticals Inc. has several key products in its pipeline, each targeting different medical conditions using reformulated versions of the drug tacrolimus. The products are in various stages of clinical trials, demonstrating the company's commitment to advancing medical research and providing new treatment options.

• LP-10: A reformulation of tacrolimus designed for patients suffering from radiation-induced hemorrhagic cystitis. This condition can arise as a complication of radiation therapy, and LP-10 has reached a promising stage of development with the completion of a Phase 2a clinical trial. The aim is to offer an effective treatment for managing the symptoms and providing relief to patients affected by this painful and debilitating condition.
• LP-310: This product represents another innovative use of tacrolimus, reformulated for the treatment of oral lichen planus — a chronic inflammatory condition that affects the mucous membranes of the mouth. LP-310 is in development to provide a targeted therapeutic option for patients dealing with the discomfort and potential complications of oral lichen planus, indicating the company's focus on addressing less common but impactful diseases.
• LP-410: An oral liposomal formulation of tacrolimus, LP-410 is under development for the treatment of oral graft-versus-host disease (GVHD). GVHD can occur after a stem cell or bone marrow transplant when the donated cells attack the recipient's body. By reformulating tacrolimus into a liposomal delivery system designed for oral administration, LP-410 aims to offer a novel and effective treatment option for managing this serious and often life-threatening condition.